Your AI-Trained Oncology Knowledge Connection!

Olivier Hermine, MD, PhD

home / authors / olivier-hermine-md-phd

Articles

Olivier Hermine, MD, PhD;Laurent Frenzel, MD, PhD;Arnaud Jaccard, MD, PhD

December 15th 2013

Because of challenges in making the correct diagnosis and the physician’s reluctance to administer chemotherapy for a disease characterized by such a low tumoral mass, patients may experience a delay in the initiation of appropriate treatment.

Rituximab Plus CHOP in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: An Update of the GELA Study

Bertrand Coiffier, MD, PhD;C. Fermé;Olivier Hermine, MD, PhD;C. Haioun;E. Baumelou;P. Solal-Celigny;A. Delmer;C. Sebban;N. Mounier;G. Tertian;A. Van Hoof;A. Bosly

March 1st 2002

At the 2000 Annual Meeting of the American Society of Hematology, we presented the benefits of rituximab (Rituxan) combined with CHOP (cyclophosphamide [Cytoxan, Neosar], doxorubicin HCl, vincristine [Oncovin], prednisone), known as R-CHOP, in comparison with CHOP alone for the treatment of elderly patients with diffuse large B-cell lymphoma (DLCL).